Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target

Syndax Pharmaceuticals is attractive because its core Revuforj franchise is showing expanding clinical and commercial traction across genetically defined AML, including a 97% CRc in frontline combination data, 86% ORR in real-world monotherapy, and durable post-HSCT outcomes with estimated 12-month OS of 95% and RFS of 79%. Even after the Phase 2 MAXPIRe miss in IPF, the broader thesis remains intact because axatilimab’s cGVHD opportunity and royalty stream were never tied to IPF, while the program continues to advance in newly diagnosed cGVHD and could still support a meaningful anti-CSF-1R franchise. Beyond near-term catalysts in 4Q26, the company adds capital-efficient optionality through SNDX-62122 in MF and SNDX-4321 in EGFR-mutated NSCLC, widening the growth runway without materially disrupting its path toward profitability.

Syndax Pharmaceuticals is a high-risk, clinical-stage biopharmaceutical company whose valuation depends heavily on future success that is still unproven, including meaningful efficacy and eventual regulatory approval for revumenib, axatilimab, and other candidates. Its pipeline is exposed to substantial clinical, competitive, and commercial uncertainty, while the need for additional equity financing raises dilution risk and underscores the lack of near-term self-funding capacity. Even the bullish framework in the excerpts relies on discounted FY32 earnings of $4.31 to $5.61, which highlights that any setback in trials, approval timelines, or market adoption could materially pressure the stock.